Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory ...

Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of ...

The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at ...

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...

PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.

Tuesday's approval makes Abrysvo the first RSV vaccine indicated for adults younger than 50, the biopharmaceutical company said. Last year, it was approved for use by those 60 years and older, as well ...

Antibodies from the Abrysvo vaccine will be passed from the mothers to the babies. Read more at straitstimes.com.

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

Analyst Mohit Bansal from Wells Fargo maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...

In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy ...